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in secondary progressive multiple sclerosis: secondary analyses 
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Summary
Background In the 24-month MS-STAT phase 2 trial, we showed that high-dose simvastatin significantly reduced the 
annualised rate of whole brain atrophy in patients with secondary progressive multiple sclerosis (SPMS). We now 
describe the results of the MS-STAT cognitive substudy, in which we investigated the treatment effect on cognitive, 
neuropsychiatric, and health-related quality-of-life (HRQoL) outcome measures.
Methods We did a secondary analysis of MS-STAT, a 24-month, double-blind, controlled trial of patients with SPMS 
done at three neuroscience centres in the UK between Jan 28, 2008, and Nov 4, 2011. Patients were randomly 
assigned (1:1) to either 80 mg simvastatin (n=70) or placebo (n=70). The cognitive assessments done were the National 
Adult Reading Test, Wechsler Abbreviated Scale of Intelligence, Graded Naming Test, Birt Memory and Information 
Processing Battery (BMIPB), Visual Object and Space Perception battery (cube analysis), Frontal Assessment 
Battery (FAB), and Paced Auditory Serial Addition Test. Neuropsychiatric status was assessed using the Hamilton 
Depression Rating Scale and the Neuropsychiatric Inventory Questionnaire. HRQoL was assessed using the self-
reported 36-Item Short Form Survey (SF-36) version 2. Assessments were done at study entry, 12 months, and 
24 months. Patients, treating physicians, and outcome assessors were masked to treatment allocation. Analyses were 
by intention to treat. MS-STAT is registered with ClinicalTrials.gov, number NCT00647348.
Findings Baseline assessment revealed impairments in 60 (45%) of 133 patients on the test of frontal lobe function 
(FAB), and in between 13 (10%) and 43 (33%) of 130 patients in tests of non-verbal and verbal memory (BMIPB). Over 
the entire trial, we noted significant worsening on tests of verbal memory (T score decline of 5·7 points, 95% CI 
3·6–7·8; p<0·0001) and non-verbal memory (decline of 6·8 points, 4·8–8·7; p<0·0001). At 24 months, the FAB score 
was 1·2 points higher in the simvastatin-treated group than in the placebo group (95% CI 0·2–2·3). The simvastatin 
group also had a 2·5 points better mean physical component score of the SF-36 (95% CI 0·3–4·8; p=0·028). A 
treatment effect was not noted for any other outcomes.
Interpretation To our knowledge, this SPMS cohort is the largest studied to date with comprehensive longitudinal 
cognitive, neuropsychiatric, and HRQoL assessments. We found evidence of a positive effect of simvastatin on frontal 
lobe function and a physical quality-of-life measure. Although we found no effect of simvastatin on the other outcome 
measures, these potential effects warrant confirmation and underline the importance of fully assessing cognition and 
quality of life in progressive multiple sclerosis treatment trials.
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Trust, a personal contribution from A W Pidgley CBE, and the National Institute for Health Research University 
College London Hospitals Biomedical Research Centre and University College London.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.
Introduction
Cognitive impairment in multiple sclerosis can 
occur from the earliest stages of the disease and its 
prevalence can exceed 80% in some studies of secondary 
progressive multiple sclerosis (SPMS).1,2 The cognitive 
domains most frequently affected in multiple 
sclerosis are speed of information processing, attention, 
episodic memory, and executive function.1 The effect of 
cognitive impairment in multiple sclerosis on daily 
function can be substantial, and greater than the effect of 
physical disability on quality-of-life measures such 
as independence, social inclusion, and mood.3 In view of 
this effect, a 2013 international position paper highlighted 
development of effective interventions to treat cognitive 
impairment as a key goal in multiple sclerosis.4
So far, most studies of cognition in SPMS have been 
cross-sectional. Longitudinal studies have largely focused 
on other multiple sclerosis subtypes such as relapsing-
remitting multiple sclerosis,5 and overall have differed 
with regard to the rate of progression of cognitive decline. 
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Some studies have reported stability, whereas others have 
described declines in patient subgroups, in specific 
domains, or in global cognition.6–8 However, detailed 
understanding of the longitudinal pattern of cognitive 
decline in observational studies, specifically in SPMS, has 
been limited by small sample sizes, with this group 
typically investigated as part of larger cohorts that also 
included patients with different multiple sclerosis 
subtypes.8,9 In a large study of patients with primary 
progressive multiple sclerosis (PPMS),7 baseline 
impairments of verbal memory, attention, verbal fluency, 
and spatial reasoning were identified, with cognitive 
decline occurring in a third of patients after 2 years.
Various methods have been used to try to improve 
cognition in patients with multiple sclerosis, including 
disease-modifying drugs, acetylcholinesterase inhibitors, 
cognitive rehabilitation, and exercise, but have yielded 
variable results with no consistent evidence of benefit.4,10 
A Cochrane review of pharmacological treatment for 
memory impairment in patients with multiple sclerosis 
concluded with no evidence of any useful pharmacological 
approach (seven trials),11 although in another Cochrane 
Research in context
Evidence before this study
We searched MEDLINE (from 1948); Embase (from 1980); and 
PubMed, the Cochrane Database of Systematic Reviews, the 
Cochrane Central Register of Controlled Trials, DARE, the Health 
Technology Assessment database, and the TRIP database (no 
date restrictions) up to April 30, 2016, for studies with the key 
words “multiple sclerosis” AND “cognition” OR 
“neuropsychiatric features” OR “SF-36” OR more general MESH 
terms for quality of life: “Health Status Indicators”, “Quality of 
Life”, “Health Status”, “Outcome Assessment (Health Care)”, 
“Health Surveys”, and “Activities of Daily Living”. We included 
trials, observational cohort studies (longitudinal and 
cross-sectional), and systematic reviews. Additionally, we 
searched abstract books from the European Committee for 
Treatment and Research in Multiple Sclerosis meetings for the 
previous 10 years. The search yielded 174 observational cohorts 
of patients with progressive multiple sclerosis (alone or mixed 
populations), of which 26 were longitudinal studies of 
cognition or neuropsychiatric symptoms, or both. After 
excluding studies in which details of the multiple sclerosis 
phenotype or results of the cognitive or neuropsychiatric 
battery were not fully defined, 19 cohorts remained: 
11 predominantly examined cognition and included two to 
31 patients with secondary progressive multiple sclerosis 
(SPMS) whose follow-up ranged from 6 months to 17 years. 
Three Cochrane reviews have been published on pharmacological 
and neuropsychological treatments of cognition or memory in 
multiple sclerosis. In the review of pharmacological approaches, 
seven randomised controlled trials of those assessed by the 
Cochrane reviewers were suitable for inclusion. Donepezil, 
ginkgo biloba, memantine, and rivastigmine were examined 
with trial sizes of 43–126 patients; the maximum number of 
patients with SPMS was 39, treatment durations were up to 
24 weeks, and all trials were judged to be negative. The original 
review of neuropsychological treatment was updated in 2014 
with 20 randomised controlled trials deemed suitable. The 
individual trial sizes were 15–240 patients, the maximum 
number of patients with SPMS was 94 (where disease subtype 
was recorded), and follow-up ranged from 4 weeks to 1 year. 
There was insufficient evidence for efficacy, in part because of 
heterogeneity of the evidence base. In 2016, the Cochrane group 
added seven new trials to its review of techniques for memory 
rehabilitation, bringing the total number of assessed trials to 15, 
of which eight were also assessed in the neuropsychological 
review. Trial sizes were 19–240 patients, the maximum number 
of patients with SPMS was 94 (where disease subtype was 
recorded), and the follow-up ranged from 5 weeks to 8 months. 
Overall, the updated Cochrane review of memory rehabilitation 
concluded there was limited evidence to support such 
interventions, particularly with regards to objective memory 
testing, and that higher-quality studies were needed.
Added value of this study
This is, to our knowledge, the largest and longest detailed 
assessment of cognition and cognitive interventions in SPMS. 
This study was done in the context of a randomised controlled 
trial of simvastatin. Baseline assessment showed impairment on 
tests of frontal lobe function and several memory domains, 
which is largely consistent with previous findings. After 2 years, 
verbal and non-verbal memory had declined significantly. 
Depression worsened, although remained mild. We noted a 
positive effect from simvastatin on frontal lobe function, 
although we identified no specific association with frontal 
atrophy using MRI. We also identified a treatment effect for 
health-related quality of life (HRQoL—physical component).
Implications of all the available evidence
This study reinforces the fact that the domains of memory 
(verbal and non-verbal) and frontal lobe function (executive 
function) are preferentially affected in SPMS compared with 
other cognitive domains and should be targeted in 
interventional trials. We found a beneficial effect of simvastatin 
on the frontal cognitive domain, as well as on the physical 
component of HRQoL, adding to the substantive effect on whole 
brain atrophy (as well as clinician-reported and 
patient-reported outcome measures) noted in the original 
MS-STAT trial. We make the following recommendation for 
future trial design for cognitive treatments in multiple sclerosis: 
focus on single phenotypes (eg, SPMS), focus on specific 
cognitive domains with high baseline impairments (frontal lobe 
function, episodic memory, and attention and speed of 
information processing), include a minimum of 12–24 months of 
follow-up, and develop MRI interim outcomes beyond 
volumetry, such as other structural measures and functional 
connectivity models.
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review, some support was noted for various 
neuropsychological rehabilitation techniques (20 trials).12 
Studies were hampered by mixed disease phenotypes, 
short durations, and differing outcome measures. A 
third Cochrane review13 concluded that there was limited 
evidence for memory rehabilition techniques and that 
more rigorous trial evidence was needed. The effects of 
exercise on cognition in multiple sclerosis has also been 
examined, with a pilot study in 42 patients showing some 
effect of high-intensity aerobic training on learning, 
memory, and attention.14
As well as cognitive impairment, neuropsychiatric 
symptoms commonly occur in multiple sclerosis, with 
approximate prevalence of 20% for depression, 9% for 
anxiety, and 5% for bipolar disorder.15 More com-
prehensive investigations have identified the occurrence 
of agitation, irritability, and apathy in multiple sclerosis.16 
The inter-relationship and directionality between 
neuropsychiatric symptoms and cognitive impairment 
remains uncertain, with some reports suggesting an 
association, but others not.5
Compared with the general population, health-related 
quality of life (HRQoL) is reduced in patients with 
multiple sclerosis, particularly in those with progressive 
disease. In a 10-year study using the 36-Item Short Form 
Survey Instrument (SF-36) to assess HRQoL, decline 
related predominantly to problems affecting physical 
status.17 In the placebo arm of the IMPACT study18 of 
interferon beta-1a versus placebo in SPMS, the mean 
change over 2 years in the SF-36 physical component was 
–0·70 (SD 8·2) and in the psychological component was 
–1·6 (9·7).
MS-STAT19 was a phase 2 trial of high-dose simvastatin 
(80 mg) in patients with SPMS. A significant 43% 
reduction in the annualised rate of whole brain atrophy 
(the primary outcome) was noted, with additional 
positive effects on clinician-reported and patient-reported 
outcome measures, namely the Expanded Disability 
Status Scale (EDSS) and Multiple Sclerosis Impact 
Scale-29 (MSIS-29v2).
The MS-STAT trial included a pre-planned secondary 
analysis of cognitive and neuropsychiatric outcome 
measures together with HRQoL, the results of which are 
presented here. These secondary analyses were designed 
to obtain  detailed longitudinal imformation on cognitive 
impairment, neuropsychiatric symptoms and HRQoL, as 
well as to identify an interventional effect of simvastatin 
in patients with SPMS.
Methods
Study design and patients
MS-STAT was a double-blind, parallel-group, random-
ised, placebo-controlled trial of simvastatin in patients 
with SPMS done at three neuroscience centres in the UK 
between Jan 28, 2008, and Nov 4, 2011. Details of MS-
STAT, including the sample size calculation, have been 
published previously.19 In brief, the key study inclusion 
criteria included age 18–65 years, EDSS score 4·0–6·5, 
and fulfilment of the revised McDonald diagnostic 
criteria for multiple sclerosis with evidence of secondary 
progression over at least the preceding 2 years.20 No 
patients were on disease-modifying treatment.
The protocol was approved by the institutional review 
board at each study site, and ethics approval was granted 
by the Berkshire Research Ethics Committee (reference 
07/Q1602/73). Patients provided written informed 
consent before entering the study.
Randomisation and masking
In MS-STAT, patients were randomly assigned (1:1) to 
receive simvastatin 80 mg daily or matching placebo for 
24 months. Randomisation was by a centralised web-
based service with minimisation on the following 
variables: age (<45 years and ≥45 years), sex (male and 
female), EDSS (4–5·5 and 6·0–6·5), centre, and 
assessing physician. Patients, treating physicians, and 
outcome assessors (including MRI scan analysts) were 
masked to treatment allocation.
Procedures
Patients received simvastatin 80 mg daily (two 40 mg 
tablets inside opaque hard gelatine capsules) or matching 
placebo (both groups received one tablet per day for the 
first month before having two per day from then on) for 
24 months. Participants were considered compliant with 
treatment if they reported taking, on average, at least 
90% of their drug at a dose of two tablets per day (80 mg 
simvastatin or matching placebo). Compliance was 
assessed by the self-reported proportion of capsules 
taken in the month before assessments at 6, 12, 18, and 
24 months. Patients were assessed at baseline and 
months 1, 6, 12, and 24, with telephone follow-up at 
months 3 and 18. Cognitive and neuropsychiatric 
assessments were done at baseline, 12 months, and 
24 months, by certified psychologists at three neuro-
science centres in southeast England or at patients’ 
homes if needed. HRQoL was assessed using the self-
reported SF-36 (version 2), which was completed by 
patients at baseline, 12 months, and 24 months.
Outcomes
Analyses of cognitive and neuropsychiatric outcome 
measures together with HRQoL were prespecified as part 
of the MS-STAT trial. We used a neuropsychological 
battery designed specifically to cover a broad range of 
cognitive domains. The cognitive tests administered 
(panel) were the National Adult Reading Test (NART; one 
measure); Wechsler Abbreviated Scale of Intelligence 
(WASI; seven measures); Graded Naming Test (GNT; one 
measure); Birt Memory and Information Processing 
Battery (BMIPB; five measures); cube analysis task from 
the Visual Object and Space Perception battery (VOSP; 
one measure); Frontal Assessment Battery (FAB; 
one measure); and Paced Auditory Serial Addition Test 
For the study protocol see 
https://www.imperial.ac.uk/
people/d.wilkie/document/581/
MS-STAT
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(PASAT-3). The NART (premorbid intelligence quotient 
[IQ]) and the figure copying measure of the BMIPB (ability 
to copy figure when placed in front of patient, assessing 
visuoperceptual function) were done at first visit only as a 
baseline; thus, 15 long itudinal cognitive outcomes were 
assessed. Neuropsychiatric status was assessed using 
the Hamilton Depression Rating Scale (HAM-D) and 
the Neuropsychiatric Inventory Questionnaire (NPIQ), 
which has two subscales—severity and distress—
representing a brief questionnaire form of the 
Neuropsychiatric Inventory. HRQoL was assessed using 
self-reported SF-36 (version 2) and standard scoring 
methods were used to convert SF-36 (version 2) scores into 
eight domains of HRQoL from which were derived a 
physical component summary (PCS), and a mental 
component summary.
We also did a post-hoc analysis of frontal lobe volumes 
(MRI scans were done in the trial at baseline, 12 months, 
and 25 months, as described previously19). The brain was 
initially parcellated using a multi-atlas propagation and 
fusion approach, as described by Cardoso and 
colleagues,21 which involves registration of atlas images 
with associated manual segmentations to each MS-STAT 
dataset. These propagated segmentations were then 
fused according to the local similarity between each atlas 
and the new images. We used the Hammers atlas as the 
multi-atlas propagation and fusion template database, 
resulting in 83 non-overlapping brain regions, 24 of 
which encompassed the frontal lobes. Because these 
regions were non-overlapping, total frontal lobe volumes 
were calculated from the summed volumes of these 
24 frontal regions. Further details of methods are 
provided in the appendix (pp 1–2 and 4–7).
Statistical analysis
All analyses were by intention to treat (ie, included 
patients in the group to which they were randomly 
assigned, regardless of compliance with the study 
protocol). Cognitive scores and HRQoL scores were 
rescaled with reference to means and SDs of a healthy 
control group (appendix p 4) to create T scores. On the 
T score scale, healthy control scores have a mean of 50 
and a SD of 10. The reference T scores were calculated 
using control means and SDs taken from test manuals 
(NART, WASI, and BMIPB) or reference papers from 
the published work (WASI and GNT). Age-specific 
control means were used for the BMIPB, for which age 
is known to be influential. The VOSP cube analysis and 
FAB scores are not normally distributed in healthy 
controls and thus unsuitable for conversion to T scores. 
Instead, these results are presented as raw scores, as are 
the measures of neuropsychiatric status and PASAT-3 
scores. PASAT-3 scores were normally distributed, but 
have been previously reported as raw scores and are 
retained in this format in this Article to preserve 
consistency with the previous report.19 Impairment on 
cognitive scores and HRQoL scores at baseline was 
defined as a score of more than 1·5 SDs below the mean 
of the reference healthy control group (appendix p 4). 
On the T score scale this is a score less than 35. 
Neuropsychiatric symptoms were assessed in terms of 
prevalence and severity. Since these are symptoms 
indicative of disease and thus not normally present in 
healthy control individuals, severity was not investigated 
in terms of differences from normative values.
We used linear mixed models to examine how HRQoL, 
cognitive scores, neuropsychiatric scores, and frontal 
lobe volumes changed between baseline, 12 months, and 
24 months, and to assess the difference in means 
between the placebo and simvastatin groups at 
12 months and 24 months. For analysis of cognitive and 
neuropsychiatric scores, we used a mixed effect model 
to compare the mean of each outcome between the 
placebo and simvastatin groups at the visits at 12 months 
and 24 months, with adjustment for minimisation 
variables. In the model, measurements made at baseline, 
12 months, and 24 months were classed as three 
correlated out comes. Interactions between treatment 
See Online for appendix
Panel: Prespecified cognitive outcome measures
•	 National	Adult	Reading	Test—assessing	premorbid	IQ*
•	 Wechsler	Abbreviated	Scale	of	Intelligence:
•	 Overall	IQ—assessing	general	intellectual	function
•	 Verbal	IQ—assessing	verbal	IQ
•	 Performance	IQ—assessing	non-verbal	IQ
•	 Vocabulary—assessing	verbal	intelligence
•	 Similarities—assessing	abstract	verbal	reasoning
•	 Block	design—assessing	spatial	perception	and	
visuomotor skills
•	 Matrix	reasoning—assessing	non-verbal	abstract	
reasoning
•	 Graded	Naming	Test—assessing	semantic	memory
•	 Birt	Memory	and	Information	Processing	Battery:
•	 Story:	immediate	recall—assessing	verbal	episodic	
memory
•	 Story:	delayed	recall—assessing	verbal	episodic	memory
•	 Figure	copying:	ability	to	copy	figure	when	placed	in	front	
of participant*—assessing visuoperceptual functioning 
•	 Figure	copying:	immediate	recall—assessing	non-verbal	
episodic memory
•	 Figure	copying:	delayed	recall—assessing	non-verbal	
episodic memory
•	 Cube	analysis	task	from	the	Visual	Object	and	Space	
Perception battery—assessing spatial perception
•	 Frontal	Assessment	Battery—assessing	executive	function	
(conceptual thinking, mental flexibility, motor 
programming, sensitivity to interference, inhibitory 
control, and environmental autonomy)
•	 Paced	Auditory	Serial	Addition	Test—assessing speed of 
information processing, attention, and working memory
*Assessed at baseline only; therefore, 15 cognitive outcomes were reported 
longitudinally. IQ=intelligence quotient. 
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group and visit were included to estimate the treatment 
effects, with that at baseline set as zero to reflect the fact 
that randomisation ensures that the true treatment 
effect at baseline is zero. We adjusted for minimisation 
variables by including interactions between visit and 
each variable. An un structured residual variance–
covariance matrix allowed for assessment of the 
correlation between repeated measures in the same 
patient. Data were included from all patients who had an 
outcome measured at one or more of the visits, providing 
an unbiased estimate of the treatment effect under the 
assumption that the model is correctly specified, and 
that data are missing at random. For each outcome, we 
estimated three separate fitted mean changes between 
baseline and 24 months from the relevant mixed effect 
model. First, we calculated the mean change for the 
cohort overall for a population with the same distribution 
of baseline values of the minimisation variables as the 
cohort as a whole, and 1:1 randomisation to treatment 
group. The other two mean changes were those for 
populations with the same distribution of minimisation 
variables as above, but with (1) all patients randomly 
assigned to placebo, and (2) all patients randomly 
assigned to simvastatin.
The mean rates of frontal lobe atrophy were compared 
between the two treatment groups using a linear mixed 
model for change per year. The model included an 
interaction between treatment group and time since 
baseline MRI as well as minimisation variables, MRI 
site, and their interactions with time. The treatment 
effect was set as zero at baseline, as described earlier. 
The model included a random intercept and random 
slope as correlated random effects, to allow for repeated 
measures.
The assumption that residuals follow a homoscedastic 
normal distribution, which is required for valid para-
metric statistical inference, was not met for VOSP, 
FAB, NPIQ distress and NPIQ severity, or HRQoL 
domains of physical functioning, role limitations–
physical, or role limitations–emotional. For these 
variables, inference was based on non-parametric, 
bias-corrected and accelerated bootstrap 95% CIs 
calculated from 2000 replications stratified by treatment 
group and clustered by patient. As a result of 
bootstrapping, p values cannot be provided. However, 
statistical significance (p<0·05) can be inferred by 
whether or not the 95% CI crosses zero. Since we class 
all the variables as of independent scientific interest, no 
formal statistical adjustments for multiple comparisons 
were made. However, the data must be interpreted with 
caution in view of the number of variables analysed. We 
used Stata (version 14.1) for all analyses. MS-STAT is 
registered with ClinicalTrials.gov, number NCT00647348.
Role of the funding source
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, writing 
of the report, or the decision to submit the manuscript. 
CF, JMN, JC, and RN had full access to all the data in the 
study; DC, SB, and DW had access to the cognitive data; 
and MJC and SO had access to the frontal lobe volumetry 
data. The corresponding author had final responsibility 
for the decision to submit for publication.
Results
140 patients were recruited to the MS-STAT trial 
(figure 1). Patient demographics were similar between 
groups, with a mean age of 51·3 years (SD 6·9), multiple 
sclerosis duration of 21·2 years (8·6), and SPMS 
duration of 7·2 years (5·2; table 1). T scores of around 50 
suggested that the premorbid IQ (derived from the 
NART) was in the normal range (table 1). At baseline, 
both study groups had similar scores on cognitive, 
neuropsychiatric, and HRQoL measures.
The proportion of patients with cognitive impairment 
at baseline differed across cognitive domains (figure 2; 
appendix p 8). Three (2%) of 131 to ten (8%) of 129 patients 
showed impairment at baseline of general intellectual 
functioning in verbal, visuomotor, or abstract reasoning 
domains, as measured by the WASI. 14 (11%) of 130 were 
Figure 1: Trial profile
408 patients assessed for eligibility
268 excluded
 107 did not meet inclusion criteria
 96 declined to participate
 65 trial recruitment closed
140 randomly assigned
70 assigned to placebo 70 assigned to simvastatin
70 received placebo 70 received simvastatin
6 lost to follow-up by 24 months
 1 unable to contact
 3 declined follow-up
 1 ill health (subarachnoid 
 haemorrhage)
    1 side-effects from study medication
15 completed 24 months of follow-up 
      but were less than 90% 
      compliant with medication
 3 were 0% compliant with 
 medication
 9 were 1–50% compliant with 
 medication
 3 were 51–89% compliant with 
 medication
3 lost to follow-up by 24 months
 1 unable to contact
 1 declined follow-up
 1 wanted to discontinue 
 study medication
15 completed 24 months of 
      follow-up but were less than 
      90% compliant with medication
 4 were 0% compliant with 
 medication
 6 were 1–50% compliant with 
         medication
 5 were 51–89% compliant with 
         medication
70 included in analyses
 64 with data at all visits
 3 with data at two visits
 3 with data at one visit
70 included in analyses
 56 with data at all visits
 7 with data at two visits
 7 with data at one visit
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impaired in semantic memory (GNT). Between 13 (10%) 
of 130 and 43 (33%) of 130 patients were impaired on 
tests of immediate and delayed verbal and non-verbal 
episodic memory recall (BMIPB story and figure scores), 
with 15 (11%) of 132 impaired on higher visual processing 
using the VOSP cube analysis. 60 (45%) of 133 patients 
exhibited impairment in executive function assessed by 
the FAB, and 62 (46%) of 134 were impaired on the 
PASAT-3.
HAM-D scores suggested that 76 (57%) of 133 patients 
had depression: 47 (35%) mild, 21 (16%) moderate, and 
eight (6%) severe or very severe. Although the NPIQ does 
not subdivide neuropsychiatric symptoms into mild, 
moderate, or severe categories, NPIQ severity (degree of 
symptoms in the patient) and distress (effect on caregiver) 
scores of 4·5 (SD 4·7) and 5·0 (5·5) were above mean 
scores of 1·5 and 1·6 for cognitively intact older adults, 
but below the mean scores of 7·9 and 9·4 associated with 
dementia disorders (appendix p1, p4).
For HRQoL, 15 (12%) of 122 patients had impairment 
in the MCS and 68 (56%) in the PCS at baseline (figure 2; 
appendix p 8). Of the eight HRQoL domains, the highest 
proportion with impairment was for physical functioning 
(109 [84%] of 130), followed by role limitations–physical 
(67 [52%]). 18 (13%) of 135 patients had impairment on 
bodily pain and 17 (13%) of 135 had impairment on 
mental health.
At 24 months, frontal lobe function (FAB scores) was 
significantly better with simvastatin treatment than  with 
placebo (difference 1·2 points, 95% CI 0·2 to 2·3; table 2). 
FAB score increased from baseline in the simvastatin 
group (change 0·3 points, 95% CI –0·4 to 0·9), whereas it 
decreased in the placebo group (change –0·9, –1·9 to –0·1; 
table 2). There was no sig nificant difference between the 
placebo and simvastatin groups for any other cognitive or 
neuropsychiatric outcome (table 2), but we noted weak 
evidence of improvement in the simvastatin group 
compared with placebo at 24 months in the WASI block 
T score (difference 2·1, 95% CI –0·1 to 4·3; p=0·064) and 
PASAT-3 score (3·9 points, –0·3 to 8·1; p=0·070). The 
appendix (p 9) shows the individual patient changes in 
the FAB score.
In terms of HRQoL, there was a significant treatment 
effect on PCS (difference 2·5 points, 95% CI 0·3 to 4·8; 
p=0·028), which corresponded to a mean increase in 
PCS of 0·7 (95% CI –1·0 to 2·3) in the simvastatin group 
and a decrease of 1·9 (0·1 to 3·6) in the placebo group. 
The appendix (pp 9, 10) shows the individual patient 
changes in PCS and MCS. There was no evidence of 
differences between the placebo and simvastatin groups 
for MCS or any of the eight individual HRQoL domains 
(table 2).
Figure 3 shows mean changes in cognitive, neuro-
psychiatric, and HRQoL outcomes between baseline and 
24 months. General intellectual functioning as measured 
by WASI did not change significantly across the duration 
of the study. There was no significant change in naming 
and verbal semantic memory (GNT). For the cohort as a 
whole, we noted the greatest decline on measures of 
delayed episodic memory recall (BMIPB), with the mean 
T-score worsening by 5·7 points (95% CI –7·8 to –3·6; 
Combined Placebo Simvastatin
N Mean (SD) N Mean (SD) N Mean (SD)
Age (years) 140 51·3 (6·9) 70 51·1 (6·8) 70 51·5 (7·0)
Multiple sclerosis duration (years) 140 21·2 (8·6) 70 20·3 (8·8) 70 22·1 (8·3)
SPMS duration (years) 140 7·2 (5·2) 70 7·1 (4·8) 70 7·3 (5·6)
Expanded Disability Status Scale 140 5·8 (0·8) 70 5·9 (0·8) 70 5·8 (0·8)
Education (years) 132 13·5 (3·2) 66 13·4 (3·3) 66 13·7 (3·1)
Premorbid verbal IQ (NART)* 135 52·7 (6·5) 68 51·7 (6·8) 67 53·7 (6·1)
Premorbid performance IQ (NART)* 135 54·7 (4·6) 68 54·0 (4·8) 67 55·4 (4·4)
Premorbid full-scale IQ(NART)* 135 53·9 (6·2) 68 53·0 (6·5) 67 54·9 (5·9)
Cognitive scores
Wechsler Abbreviated Scale of Intelligence*
Overall IQ 130 53·1 (9·6) 66 53·4 (9·6) 64 52·8 (9·8)
Verbal	IQ 131 54·5 (9·5) 66 54·1 (9·7) 65 54·8 (9·3)
Performance IQ 130 51·1 (9·5) 66 51·8 (9·1) 64 50·4 (10·0)
Vocabulary 130 56·0 (10·2) 65 55·9 (9·3) 65 56·1 (11·1)
Similarities 129 51·4 (9·3) 63 51·0 (9·6) 66 51·8 (9·0)
Block design 129 48·2 (9·2) 64 48·6 (9·0) 65 47·7 (9·5)
Matrix reasoning 129 53·4 (10·5) 65 54·6 (9·4) 64 52·2 (11·4)
Graded	Naming	Test* 130 53·2 (12·2) 66 52·8 (12·0) 64 53·6 (12·6)
Birt Memory and Information Processing Battery*
Story immediate 131 43·2 (10·7) 66 42·7 (9·8) 65 43·7 (11·7)
Story delay 131 43·7 (10·7) 66 43·1 (9·4) 65 44·3 (11·9)
Figure copying 130 48·5 (11·5) 66 49·3 (12·1) 64 47·7 (10·8)
Figure copying: immediate recall 130 41·0 (11·1) 66 40·5 (11·2) 64 41·5 (11·0)
Figure copying: delayed recall 130 46·4 (9·2) 66 46·4 (9·4) 64 46·4 (9·1)
VOSP	cube	analysis 132 9·2 (1·6) 67 9·3 (1·5) 65 9·1 (1·7)
Frontal Assessment Battery 133 16·1 (2·4) 67 15·9 (2·5) 66 16·3 (2·4)
Paced Auditory Serial Addition Test 134 34·2 (15·0) 67 33·7 (16·1) 67 34·8 (13·8)
Neuropsychiatric scores
Hamilton Depression Rating Scale 133 9·2 (6·2) 67 9·3 (6·1) 66 9·1 (6·3)
NPIQ severity 112 4·5 (4·7) 55 4·9 (5·2) 57 4·1 (4·1)
NPIQ distress 112 5·0 (5·5) 55 5·6 (6·1) 57 4·3 (4·7)
Health-related quality of life*
Mental component score 122 48·9 (11·1) 59 47·9 (12·6) 63 49·8 (9·5)
Physical component score 122 33·7 (8·7) 59 32·8 (8·5) 63 34·5 (8·9)
Physical functioning 130 27·1 (8·8) 62 25·6 (7·9) 68 28·4 (9·3)
Role limitations physical 130 35·8 (9·9) 64 36·0 (10·2) 66 35·7 (9·7)
Bodily pain 135 48·4 (11·4) 66 46·3 (11·6) 69 50·4 (10·9)
General	health 131 39·6 (10·7) 65 39·1 (9·7) 66 40·1 (11·6)
Vitality 130 42·4 (9·0) 65 42·2 (9·5) 65 42·7 (8·4)
Social functioning 134 39·2 (11·8) 66 38·0 (11·9) 68 40·3 (11·7)
Role limitations emotional 133 44·3 (13·7) 66 43·8 (14·0) 67 44·8 (13·5)
Mental health 131 47·3 (9·9) 64 45·9 (10·6) 67 48·6 (9·1)
Premorbid IQ data were considered a baseline demographic characteristic, against which cognitive data could be 
compared. SPMS=secondary progressive multiple sclerosis. IQ=intelligence quotient. NART=National Adult Reading 
Test.	VOSP=Visual	Object	and	Space	Perception.	NPIQ=Neuropsychiatric	Inventory	Questionnaire.	*T	score	(mean	50	
[SD 10] in healthy reference population).
Table 1: Baseline characteristics of participants
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p<0·0001) for delayed verbal recall and by 6·8 points 
(–8·7 to –4·8; p<0·0001) for non-verbal recall. Immediate 
verbal episodic recall showed a mean decline of 
2·5 points (–4·5 to –0·4; p=0·018), but the 1·8 point drop 
in immediate non-verbal episodic recall was not 
significant (–4·1 to 0·5; p=0·12). There was no significant 
change in spatial perception (VOSP). There was an 
increase of 2·8 points (1·5 to 4·0) on the HAM-D 
(p<0·0001), although 64 (68%) of 94 patients’ scores at 
24 months still suggested either no depression or mild 
depression. There was no significant change in mean 
NPIQ severity or distress scores. Neither the MCS nor 
PCS HRQoL changed significantly between baseline and 
24 months for the cohort as a whole. However, as 
mentioned earlier, the mean PCS decreased in the 
placebo group, but did not change substantially in the 
simvastatin group. Of the individual HRQoL domains, 
there was a 2·5 point decline in mean physical 
functioning score, whereas the other domains did not 
change significantly between baseline and 24 months.
In view of the effect on frontal lobe function, we did a 
post-hoc analysis using frontal lobe volumetry, which 
was judged to be the most appropriate technique for our 
stated region of interest. We noted no significant 
difference in the rate of change in frontal lobe volume 
between the simvastatin and placebo groups (table 2). 
There was no evidence of an association between change 
in FAB score between baseline and 24 months and 
change in frontal lobe volume between baseline and 
25 months, either in the placebo (Spearman rank 
correlation 0·17; p=0·29; n=40) or simvastatin (–0·19; 
p=0·21; n=45) group.
Discussion
This is, to our knowledge, the largest reported cohort of 
patients with SPMS to have undergone detailed longi-
tudinal assessment of cognition, neuropsychiatric status, 
and HRQoL. At baseline, the most prominent cognitive 
deficits were in attention and speed of information 
processing, frontal lobe function, verbal and non-verbal 
recall, and working memory. This profile is similar to 
that reported previously in other cross-sectional SPMS 
groups.2,22–24
In terms of the effect of simvastatin on cognition, over 
the 24-month trial, changes in the overall cognitive profile 
were similar for both simvastatin and placebo groups, 
with no effect of simvastatin on most cognitive domains. 
However, there was evidence of a positive treatment effect 
on frontal lobe function, assessed using the FAB. Overall 
cognitive decline was greatest in verbal and non-verbal 
episodic memory recall, without significant changes in 
general intellectual function, naming, or higher visual 
processing. Although the much smaller cohorts of 
previous longitudinal SPMS studies (generally 20% of this 
study) precludes like-for-like comparison, changes over 
time were noted in episodic memory, learning, attention, 
speed of information, and visual processing.6,8,9
In terms of neuropsychiatric outcome measures, over 
24 months, depression increased significantly, as 
determined by the HAM-D score, and there was a non-
significant increase in NPIQ severity and distress scores, 
although no treatment effect was noted on any 
neuropsychiatric outcome measure.
The potential treatment effect on frontal lobe function 
warrants further discussion. Several studies have 
described impaired frontal lobe function in multiple 
sclerosis,22–26 and a recent, large cross-sectional study,25 
including 74 patients with SPMS, revealed a heavy burden 
of executive dysfunction in all progressive multiple 
sclerosis subtypes. Although Ruano and colleagues25 
showed patients with PPMS more frequently had 
executive dysfunction compared with patients with other 
subtypes of multiple sclerosis, others have shown frontal 
lobe capabilities to be affected to a greater extent in SPMS 
than in PPMS.22–24 In one study of patients with relapsing-
remitting multiple sclerosis, impairment of frontal 
executive function was noted in the context of otherwise 
intact cognitive function,26 suggesting that this cognitive 
domain might be one of the earliest affected in multiple 
sclerosis. However, the reason for the apparently selective 
effect of simvastatin on frontal lobe function is unclear. 
There is no obvious pharmacological reason based on the 
current understanding of the mode of action of 
simvastatin that would result in a preferential 
improvement in frontal lobe function. Therefore, this 
finding might be due in part to the study population, in 
particular the level of impairment at baseline, with the 
FAB being one of the tests in which the greatest 
proportion of patients were affected (about 45%). As 
such, any treatment effect on other cognitive tests might 
have been more subtle, because proportionally fewer 
Figure 2: Percentage of patients impaired in each measure at baseline in both groups combined
Numerators and denominators used to calculate these percentages are provided in the appendix (p 8). 
WASI=Wechsler Abbreviated Scale of Intelligence. IQ=intelligence quotient. BMIPB=Birt Memory and Information 
Processing	Battery.	VOSP=Visual	Object	and	Space	Perception.	HRQoL=health-related	quality	of	life.	MCS=mental	
component score. PCS=physical component score.
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patients were impaired, and this study did not have 
sufficient power to detect these effects.
Various methods have been used in previous studies to 
assess frontal lobe function in multiple sclerosis, 
including bespoke frontal lobe test batteries,24 or as part 
of tests within global batteries such as the MindStreams 
Global Assessment Battery23 or Brief Repeatable Battery,7,9 
in some cases augmented by additional frontal lobe 
assessments.25 The FAB was chosen for this study in view 
of its ability to probe differing aspects of frontal lobe 
function, for which it has been used widely in the study 
of patients with fronto temporal dementia and other 
neurodegenerative disorders affecting the frontal lobes. 
Furthermore, the reproducibility and ease of 
administration of the FAB confers advantages in terms of 
application to large multiple sclerosis cohorts. The FAB 
Combined Placebo Simvastatin Treatment effect 
(95% CI)
p value
N Change (95% CI) p value N Change (95% CI) N Change (95% CI)
Cognitive scores
Wechsler Abbreviated Scale of Intelligence*
Overall IQ 135 –0·2 (–1·4 to 0·9) 0·67 68 –0·3 (–1·9 to 1·3) 67 –0·2 (–1·7 to 1·3) 0·1 (–2·0 to 2·2) 0·92
Verbal	IQ 136 –1·4 (–2·8 to 0·0) 0·058 68 –1·2 (–3·2 to 0·7) 68 –1·5 (–3·4 to 0·3) –0·3 (–2·8 to 2·2) 0·82
Performance IQ 135 0·8 (–0·2 to 1·8) 0·13 68 0·3 (–1·1 to 1·8) 67 1·2 (–0·1 to 2·6) 0·9 (–1·0 to 2·9) 0·35
Vocabulary 137 –1·2 (–3·0 to 0·5) 0·17 68 –1·3 (–3·7 to 1·1) 69 –1·1 (–3·4 to 1·2) 0·2 (–2·9 to 3·3) 0·90
Similarities 136 –0·8 (–2·3 to 0·7) 0·30 67 –0·6 (–2·7 to 1·5) 69 –1·0 (–2·9 to 1·0) –0·3 (–3·1 to 2·4) 0·80
Block design 136 0·6 (–0·5 to 1·7) 0·29 68 –0·4 (–2·0 to 1·2) 68 1·6 (0·1 to 3·2) 2·1 (–0·1 to 4·3) 0·064
Matrix reasoning 136 0·9 (–0·8 to 2·6) 0·30 68 1·4 (–1·0 to 3·8) 68 0·4 (–1·9 to 2·7) –1·0 (–4·2 to 2·2) 0·55
Graded	Naming	Test* 135 –0·5 (–1·7 to 0·7) 0·44 68 –0·3 (–2·0 to 1·4) 67 –0·7 (–2·3 to 0·9) –0·4 (–2·7 to 1·9) 0·75
Birt Memory and Information Processing Battery*
Story: immediate recall 136 –2·5 (–4·5 to –0·4) 0·018 68 –3·0 (–6·0 to –0·1) 68 –2·0 (–4·7 to 0·8) 1·1 (–2·9 to 5·0) 0·60
Story: delayed recall 136 –5·7 (–7·8 to –3·6) <0·0001 68 –6·5 (–9·5 to –3·4) 68 –5·0 (–7·8 to –2·1) 1·5 (–2·6 to 5·7) 0·47
Figure copying: 
immediate recall
135 –1·8 (–4·1 to 0·5) 0·12 68 –1·4 (–4·8 to 1·9) 67 –2·2 (–5·3 to 0·8) –0·8 (–5·2 to 3·6) 0·72
Figure copying: 
delayed recall
135 –6·8 (–8·7 to –4·8) <0·0001 68 –7·0 (–9·9 to –4·2) 67 –6·5 (–9·1 to –3·9) 0·5 (–3·4 to 4·4) 0·79
VOSP	cube	analysis† 137 0·0 (–0·3 to 0·3) ·· 69 0·0 (–0·4 to 0·3) 68 0·0 (–0·4 to 0·4) 0·0 (–0·5 to 0·5) ··
Frontal	Assessment	Battery† 138 –0·3 (–0·9 to 0·3) ·· 69 –0·9 (–1·9 to –0·1) 69 0·3 (–0·4 to 0·9) 1·2 (0·2 to 2·3) ··
Paced Auditory Serial 
Addition Test
140 2·0 (–0·2 to 4·2) 0·074 70 0·0 (–3·1 to 3·2) 70 3·9 (1·0 to 6·8) 3·9 (–0·3 to 8·1) 0·070
Neuropsychiatric measures
Hamilton Depression 
Rating Scale
138 2·8 (1·5 to 4·0) <0·0001 69 3·3 (1·6 to 5·0) 69 2·3 (0·7 to 3·8) –1·0 (–3·2 to 1·2) 0·37
NPIQ	severity† 127 0·5 (–0·7 to 1·7) ·· 64 0·7 (–0·7 to 2·6) 63 0·2 (–1·4 to 1·6) –0·6 (–2·7 to 1·6) ··
NPIQ	distress† 127 1·0 (–0·4 to 2·5) ·· 64 1·6 (–0·5 to 3·9) 63 0·3 (–1·3 to 1·9) –1·3 (–3·9 to 1·1) ··
Health-related quality of life*
Mental component score 136 –0·8 (–3·0 to 1·4) 0·48 67 –0·7 (–3·8 to 2·3) 69 –0·8 (–3·7 to 2·0) –0·1 (–4·0 to 3·8) 0·96
Physical component score 136 –0·6 (–1·9 to 0·7) 0·36 67 –1·9 (–3·6 to –0·1) 69 0·7 (–1·0 to 2·3) 2·5 (0·3 to 4·8) 0·028
Physical	functioning† 138 –2·5 (–3·8 to –1·4) ·· 68 –2·3 (–4·0 to –0·7) 70 –2·8 (–4·4 to –1·4) –0·5 (–2·8 to 1·5) ··
Role	limitations–physical† 137 0·8 (–1·2 to 2·7) ·· 68 –0·5 (–2·9 to 1·9) 69 2·1 (–0·6 to 4·8) 2·6 (–0·7 to 6·0) ··
Bodily pain 139 –1·0 (–2·6 to 0·7) 0·24 69 –1·7 (–4·0 to 0·7) 70 –0·3 (–2·5 to 1·9) 1·4 (–1·7 to 4·4) 0·39
General	health 139 –0·1 (–1·6 to 1·4) 0·89 69 0·1 (–2·1 to 2·3) 70 –0·3 (–2·3 to 1·7) –0·4 (–3·3 to 2·4) 0·77
Vitality 137 0·2 (–1·4 to 1·8) 0·82 68 0·3 (–1·9 to 2·6) 69 0·0 (–2·1 to 2·2) –0·3 (–3·2 to 2·7) 0·85
Social functioning 139 –1·9 (–4·2 to 0·5) 0·12 69 –0·8 (–4·0 to 2·4) 70 –2·9 (–5·9 to 0·1) –2·1 (–6·2 to 2·0) 0·31
Role	limitations–emotional† 139 –1·4 (–4·1 to 1·3) ·· 69 –2·3 (–6·0 to 1·3) 70 –0·5 (–4·2 to 2·9) 1·8 (–2·9 to 6·3) ··
Mental health 138 –1·3 (–3·2 to 0·6) 0·19 68 –0·5 (–3·1 to 2·1) 70 –2·0 (–4·5 to 0·4) –1·5 (–4·9 to 1·9) 0·38
MRI
Frontal lobe atrophy 
(mL/year)‡
140 –1·0 (–1·3 to –0·6) <0·0001 70 –1·0 (–1·5 to –0·4) 70 –0·9 (–1·4 to –0·4) 0·0 (–0·7 to 0·7) 0·97
Imaging	was	done	between	baseline	and	25	months.	IQ=intelligence	quotient.	VOSP=Visual	Object	and	Space	Perception.	NPIQ=Neuropsychiatric	Inventory	Questionnaire.	
*T	score.	†As	a	result	of	bootstrapping,	p	values	cannot	be	provided;	however,	significance	(p<0·05)	can	be	inferred	by	the	95%	CI	not	crossing	zero.	‡Post-hoc	analysis.
Table 2: Changes in cognitive and neuropsychiatric scores, health-related quality of life, and frontal lobe volume between baseline and 24 months
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has previously been used in patients with multiple 
sclerosis, principally in studies focused on assessment of 
quality of life and coping strategies, but also as part of an 
executive function battery.2,27 To our knowledge, this is the 
first study to use the FAB as an independently reported 
cognitive outcome measure within a longitudinal inter-
ventional study, and the study findings show the 
importance of including a comprehensive assessment of 
frontal lobe function in future multiple sclerosis 
interventional studies, either as an individual outcome 
measure or in addition to current batteries such as the 
Brief International Cognitive Assessment for MS.5
By contrast with the treatment effect on whole brain 
atrophy rates reported previously,19 we noted no 
significant effect on rates of frontal lobe atrophy, and 
there was no significant correlation between FAB scores 
and rates of frontal lobe atrophy. Several potential 
explanations exist for this apparent dissociation. Other 
imaging measures might be superior predictors of 
executive function than atrophy.5,28 Corpus callosum 
atrophy might outperform other imaging markers of 
cognitive dysfunction, such as grey or white matter 
fraction, and tracked over 17 years, was associated with 
cognitive dysfunction in multiple sclerosis subtypes 
including SPMS;29 other studies have used resting-state 
functional MRI to identify an association between 
cognitive impairment and altered functional con-
nectivity.5 More recently, techniques such as thalamic 
volume and activation28,30 and cortical lesions visible via 
high-field MRI31 have shown associations with cognition.
We also showed evidence that simvastatin treatment 
had a positive effect on physical HRQoL, as measured 
using the SF-36 (version 2) PCS. This finding is 
consistent with the positive treatment effect on the EDSS 
and MSIS-29v2 (especially the physical subscale) 
previously repor ted.19 The absence of effect on the mental 
component scale of the HRQoL is consistent with the 
absence of effect on the neuro psychiatric outcome 
measures and MSIS-29v2 psycho logical subscale.
This study has several limitations. First, in view of the 
need for comprehensive assessment of cognition and 
neuropsychiatric status, this study involved analysis of 
data from 15 cognitive outcomes and three neuro-
psychiatric outcomes. Caution is therefore warranted in 
the interpretation of the evidence of a positive treatment 
effect on the measure of frontal lobe function and 
confirmation of this finding in independent studies is 
needed. The fluctuating nature of disease activity in all 
patients with multiple sclerosis, and its susceptibility to 
environmental factors such as heat and concomitant 
illness, are confounders in the study of cognitive 
function in multiple sclerosis.32 Such fluctuations might 
lead to variability in test performance, which would 
reduce the power of the study to detect an effect of 
treatment on cognition. Although patients were screened 
for possible concurrent acute medical disorders at each 
study visit, the possibility of variability in test 
performance as a result of external factors cannot be 
entirely excluded. The effect of patient dropout on data 
analysis also needs to be considered. However, this effect 
was offset in this study by the use of a statistical model 
that maximised data inclusion by incorporating all 
available cognitive assessments for all patients, thus 
ensuring that the estimated treatment effect was 
unbiased if data were missing at random.
In conclusion, we found evidence of a positive effect of 
treatment with high-dose simvastatin on frontal lobe 
function and a physical quality-of-life measure, adding to 
our previous findings of a treatment effect on the 
annualised rate of whole brain atrophy.19
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baseline and 24 months in both groups combined
Bars are 95% CIs. In all tests, except HAM-D and NPIQ, a positive change suggests improvement. WASI=Wechsler 
Abbreviated Scale of Intelligence. IQ=intelligence quotient. BMIPB=Birt Memory and Information Processing 
Battery.	VOSP=Visual	Object	and	Space	Perception.	HAM-D=Hamilton	Depression	Rating	Scale.	
NPIQ=Neuropsychiatric Inventory Questionnaire. HRQoL=health-related quality of life. MCS=mental component 
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